You can access any of the podium or poster presentations’ abstracts by searching for it below. For the 2026 FIP world congress in Montreal, presentations and summaries from invited speakers are available below, while abstracts are published in the Pharmacy Education Journal (PEJ) here.
Export this Abstract | Print this Abstract |
Add to my preferred Abstracts list |
My preferred Abstracts list (0) |
Back to Search
Facility design for manufacture of cell therapy products
- In: Hospital Pharmacy Section - Poster session
- At: Cairo (Egypt) (2005)
- Type: Poster
- Poster code: HPS-P-033
- By: GALLELLI, Joseph (National Institutes of Health, The Clinical Center, Bethesda, Maryland, United States of America)
- Co-author(s): Sabra (Pharmaceutical Services, DUBLIN, Ireland)
Carter (National Institutes of Health, BETHESDA, MARYLAND, United States of America) - Abstract:
U.S. medical centers and hospitals manufacturing cell and gene therapy
products, including products for clinical trials, are required by the Food
and Drug Administration to follow current Good manufacturing Practice
(cGMP) regulations. This provides assurance that there is consistency
between lots and that adequate controls are in place to.. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.
Please login
Last update 23 September 2026